Like comment and I'll do the s_老虎社区_美港股上老虎

2021-05-18

Like comment and I'll do the same :)

These 2 Nasdaq Stock Winners Could Change the World<blockquote>这两位纳斯达克股票赢家可能会改变世界</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":194026775,"tweetId":"194026775","gmtCreate":1621327645097,"gmtModify":1634192417529,"author":{"id":3569410609498781,"idStr":"3569410609498781","authorId":3569410609498781,"authorIdStr":"3569410609498781","name":"MrRoboto","avatar":"https://static.tigerbbs.com/2146fc07559faee2ded0d703a76a8ce9","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Like comment and I'll do the same :)</body></html>","htmlText":"<html><head></head><body>Like comment and I'll do the same :)</body></html>","text":"Like comment and I'll do the same :)","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/194026775","repostId":1157626171,"repostType":4,"repost":{"id":"1157626171","kind":"news","pubTimestamp":1621309064,"share":"https://www.laohu8.com/m/news/1157626171?lang=zh_CN&edition=full","pubTime":"2021-05-18 11:37","market":"us","language":"en","title":"These 2 Nasdaq Stock Winners Could Change the World<blockquote>这两位纳斯达克股票赢家可能会改变世界</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1157626171","media":"fool","summary":"The stock market had a tough day on Monday, and once again, negative attention centered on theNasdaq","content":"The stock market had a tough day on Monday, and once again, negative attention centered on theNasdaq Composite(NASDAQINDEX:^IXIC). The index's 1% drop as of 2:15 p.m. EDT was bigger than what other major market benchmarks faced, in part because the appetite for high-priced stocks seems to have waned considerably over the past few months.<blockquote>周一股市经历了艰难的一天，负面关注再次集中在纳斯达克复合材料（纳斯达克指数：^IXIC）。截至下午2:15，该指数下跌1%。美国东部时间比其他主要市场基准面临的情况更大，部分原因是过去几个月对高价股票的兴趣似乎大幅减弱。</blockquote> However, a couple of Nasdaq stocks were big winners on Monday, and they both have innovative business models that could have a positive influence on the world.&nbsp;AppHarvest(NASDAQ:APPH)&nbsp;and&nbsp;Summit Therapeutics(NASDAQ:SMMT)had notable gains to start the week. Below, we'll go into the details to see why investors are paying close attention to these two Nasdaq winners.<blockquote>然而，周一有几只纳斯达克股票成为大赢家，它们都拥有创新的商业模式，可以对世界产生积极影响。AppHarvest（纳斯达克：APPH）及顶峰治疗公司（纳斯达克：SMMT）本周初涨幅显着。下面，我们将详细了解投资者为何密切关注这两位纳斯达克获奖者。</blockquote> Investors are feeding on this stock<blockquote>投资者正在买入这只股票</blockquote> Shares of AppHarvest had a solid gain of more than 8% on Monday afternoon. The stock only recently came public through a merger with aspecial purpose acquisition company, and this was the first chance that investors had to see the sustainable-farming company's full potential.<blockquote>周一下午，AppHarvest股价大幅上涨超过8%。该股票最近才通过与aspecial purpose acquisition company合并上市，这是投资者第一次有机会看到这家可持续农业公司的全部潜力。</blockquote> AppHarvest released its first-quarter financial reporton Monday, and shareholders liked what they saw. The company posted $2.3 million in revenue in its first operational quarter, selling 3.8 million pounds of tomatoes from its first greenhouse facility in Kentucky. AppHarvest posted considerable losses, as expected, but it has high hopes for the future.<blockquote>AppHarvest周一发布了第一季度财务报告，股东们对他们所看到的感到满意。该公司在第一个运营季度的收入为230万美元，从肯塔基州的第一个温室设施销售了380万磅西红柿。正如预期的那样，AppHarvest出现了相当大的亏损，但它对未来寄予厚望。</blockquote> In particular, AppHarvest said that it had fully planted its 60-acre facility as of the first week of May, which should lead to capacity harvests for the foreseeable future as indoor farming makes all-year growing possible. The company has seen strong demand from customers like grocery-giantKroger&nbsp;and fast-food restaurant chainWendy's&nbsp;and anticipates more interest as it develops additional facilities.<blockquote>特别是，AppHarvest表示，截至5月第一周，其60英亩的设施已完全种植，这应该会在可预见的未来带来产能收获，因为室内农业使全年种植成为可能。该公司看到了杂货巨头等客户的强劲需求克罗格和快餐店连锁店温迪的并预计随着其开发更多设施而引起更多兴趣。</blockquote> AppHarvest won't be profitable in the near term, but shareholders are still excited about its growth potential. With sustainable farming potentially making it possible to feed an increasingly hungry world, the stock is an interesting way to invest in agriculture.<blockquote>AppHarvest短期内不会盈利，但股东仍然对其增长潜力感到兴奋。随着可持续农业有可能养活日益饥饿的世界，该股票是投资农业的一种有趣方式。</blockquote> Here's a healthy pick<blockquote>这是一个健康的选择</blockquote> Meanwhile, Summit Therapeutics did even better, as its stock soared 22%. The developmental-stage biopharmaceutical company's financial report didn't feature very attractive numbers, but investors are optimistic about the progress it has made recently.<blockquote>与此同时，Summit Therapeutics的表现甚至更好，其股价飙升22%。这家处于发展阶段的生物制药公司的财务报告没有非常吸引人的数据，但投资者对其最近取得的进展持乐观态度。</blockquote> Summit's financials were predictably ugly. Revenue was just $192,000, leading to losses of $17.5 million. Summit is burning cash to conduct clinical trials, and until one of the treatments in the company's pipeline pans out, investors can expect those losses to continue. However, the company noted that CEO and majority shareholder Robert Duggan provided an additional $55 million in debt financing during the first three months of 2021, helping to boost Summit's cash levels back above the $100 million mark.<blockquote>不出所料，Summit的财务状况很糟糕。收入仅为19.2万美元，导致亏损1750万美元。Summit正在烧钱进行临床试验，在该公司正在研发的一种治疗方法取得成功之前，投资者预计这些损失将持续下去。然而，该公司指出，首席执行官兼大股东Robert Duggan在2021年前三个月额外提供了5500万美元的债务融资，帮助Summit的现金水平回升至1亿美元以上。</blockquote> Moreover, Summit had promising news in its business update. Phase 3 trials for its ridinilazole antibiotic are ongoing, with support from the federal government's Biomedical Advanced Research and Development Authority. Moreover, the company just launched a new study for adolescents, hoping to establish a favorable safety profile as a complement to its concurrent phase 3 program.<blockquote>此外，Summit在其业务更新中也有令人鼓舞的消息。在联邦政府生物医学高级研究与发展局的支持下，其利地尼唑抗生素的3期试验正在进行中。此外，该公司刚刚启动了一项针对青少年的新研究，希望建立良好的安全性概况，作为其并行3期计划的补充。</blockquote> Summit's share price has been volatile as investors try to determine whether the company will find success with its clinical program. As with most companies in the industry, Summit could see either massive upside or suffer big losses depending on what happens with ridinilazole and the other candidates in its pipeline.<blockquote>随着投资者试图确定该公司的临床项目是否会取得成功，Summit的股价一直波动。与业内大多数公司一样，Summit可能会看到巨大的上涨空间，也可能会遭受巨大损失，具体取决于ridinilazole和其管道中其他候选药物的情况。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 2 Nasdaq Stock Winners Could Change the World<blockquote>这两位纳斯达克股票赢家可能会改变世界</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 2 Nasdaq Stock Winners Could Change the World<blockquote>这两位纳斯达克股票赢家可能会改变世界</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nfool2021-05-18 11:37\n\n</h4>\n</header>\n<article>\nThe stock market had a tough day on Monday, and once again, negative attention centered on theNasdaq Composite(NASDAQINDEX:^IXIC). The index's 1% drop as of 2:15 p.m. EDT was bigger than what other major market benchmarks faced, in part because the appetite for high-priced stocks seems to have waned considerably over the past few months.<blockquote>周一股市经历了艰难的一天，负面关注再次集中在纳斯达克复合材料（纳斯达克指数：^IXIC）。截至下午2:15，该指数下跌1%。美国东部时间比其他主要市场基准面临的情况更大，部分原因是过去几个月对高价股票的兴趣似乎大幅减弱。</blockquote> However, a couple of Nasdaq stocks were big winners on Monday, and they both have innovative business models that could have a positive influence on the world.&nbsp;AppHarvest(NASDAQ:APPH)&nbsp;and&nbsp;Summit Therapeutics(NASDAQ:SMMT)had notable gains to start the week. Below, we'll go into the details to see why investors are paying close attention to these two Nasdaq winners.<blockquote>然而，周一有几只纳斯达克股票成为大赢家，它们都拥有创新的商业模式，可以对世界产生积极影响。AppHarvest（纳斯达克：APPH）及顶峰治疗公司（纳斯达克：SMMT）本周初涨幅显着。下面，我们将详细了解投资者为何密切关注这两位纳斯达克获奖者。</blockquote> Investors are feeding on this stock<blockquote>投资者正在买入这只股票</blockquote> Shares of AppHarvest had a solid gain of more than 8% on Monday afternoon. The stock only recently came public through a merger with aspecial purpose acquisition company, and this was the first chance that investors had to see the sustainable-farming company's full potential.<blockquote>周一下午，AppHarvest股价大幅上涨超过8%。该股票最近才通过与aspecial purpose acquisition company合并上市，这是投资者第一次有机会看到这家可持续农业公司的全部潜力。</blockquote> AppHarvest released its first-quarter financial reporton Monday, and shareholders liked what they saw. The company posted $2.3 million in revenue in its first operational quarter, selling 3.8 million pounds of tomatoes from its first greenhouse facility in Kentucky. AppHarvest posted considerable losses, as expected, but it has high hopes for the future.<blockquote>AppHarvest周一发布了第一季度财务报告，股东们对他们所看到的感到满意。该公司在第一个运营季度的收入为230万美元，从肯塔基州的第一个温室设施销售了380万磅西红柿。正如预期的那样，AppHarvest出现了相当大的亏损，但它对未来寄予厚望。</blockquote> In particular, AppHarvest said that it had fully planted its 60-acre facility as of the first week of May, which should lead to capacity harvests for the foreseeable future as indoor farming makes all-year growing possible. The company has seen strong demand from customers like grocery-giantKroger&nbsp;and fast-food restaurant chainWendy's&nbsp;and anticipates more interest as it develops additional facilities.<blockquote>特别是，AppHarvest表示，截至5月第一周，其60英亩的设施已完全种植，这应该会在可预见的未来带来产能收获，因为室内农业使全年种植成为可能。该公司看到了杂货巨头等客户的强劲需求克罗格和快餐店连锁店温迪的并预计随着其开发更多设施而引起更多兴趣。</blockquote> AppHarvest won't be profitable in the near term, but shareholders are still excited about its growth potential. With sustainable farming potentially making it possible to feed an increasingly hungry world, the stock is an interesting way to invest in agriculture.<blockquote>AppHarvest短期内不会盈利，但股东仍然对其增长潜力感到兴奋。随着可持续农业有可能养活日益饥饿的世界，该股票是投资农业的一种有趣方式。</blockquote> Here's a healthy pick<blockquote>这是一个健康的选择</blockquote> Meanwhile, Summit Therapeutics did even better, as its stock soared 22%. The developmental-stage biopharmaceutical company's financial report didn't feature very attractive numbers, but investors are optimistic about the progress it has made recently.<blockquote>与此同时，Summit Therapeutics的表现甚至更好，其股价飙升22%。这家处于发展阶段的生物制药公司的财务报告没有非常吸引人的数据，但投资者对其最近取得的进展持乐观态度。</blockquote> Summit's financials were predictably ugly. Revenue was just $192,000, leading to losses of $17.5 million. Summit is burning cash to conduct clinical trials, and until one of the treatments in the company's pipeline pans out, investors can expect those losses to continue. However, the company noted that CEO and majority shareholder Robert Duggan provided an additional $55 million in debt financing during the first three months of 2021, helping to boost Summit's cash levels back above the $100 million mark.<blockquote>不出所料，Summit的财务状况很糟糕。收入仅为19.2万美元，导致亏损1750万美元。Summit正在烧钱进行临床试验，在该公司正在研发的一种治疗方法取得成功之前，投资者预计这些损失将持续下去。然而，该公司指出，首席执行官兼大股东Robert Duggan在2021年前三个月额外提供了5500万美元的债务融资，帮助Summit的现金水平回升至1亿美元以上。</blockquote> Moreover, Summit had promising news in its business update. Phase 3 trials for its ridinilazole antibiotic are ongoing, with support from the federal government's Biomedical Advanced Research and Development Authority. Moreover, the company just launched a new study for adolescents, hoping to establish a favorable safety profile as a complement to its concurrent phase 3 program.<blockquote>此外，Summit在其业务更新中也有令人鼓舞的消息。在联邦政府生物医学高级研究与发展局的支持下，其利地尼唑抗生素的3期试验正在进行中。此外，该公司刚刚启动了一项针对青少年的新研究，希望建立良好的安全性概况，作为其并行3期计划的补充。</blockquote> Summit's share price has been volatile as investors try to determine whether the company will find success with its clinical program. As with most companies in the industry, Summit could see either massive upside or suffer big losses depending on what happens with ridinilazole and the other candidates in its pipeline.<blockquote>随着投资者试图确定该公司的临床项目是否会取得成功，Summit的股价一直波动。与业内大多数公司一样，Summit可能会看到巨大的上涨空间，也可能会遭受巨大损失，具体取决于ridinilazole和其管道中其他候选药物的情况。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/05/17/these-2-nasdaq-stock-winners-could-change-world/\">fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"source_url":"https://www.fool.com/investing/2021/05/17/these-2-nasdaq-stock-winners-could-change-world/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157626171","content_text":"The stock market had a tough day on Monday, and once again, negative attention centered on theNasdaq Composite(NASDAQINDEX:^IXIC). The index's 1% drop as of 2:15 p.m. EDT was bigger than what other major market benchmarks faced, in part because the appetite for high-priced stocks seems to have waned considerably over the past few months.\nHowever, a couple of Nasdaq stocks were big winners on Monday, and they both have innovative business models that could have a positive influence on the world. AppHarvest(NASDAQ:APPH) and Summit Therapeutics(NASDAQ:SMMT)had notable gains to start the week. Below, we'll go into the details to see why investors are paying close attention to these two Nasdaq winners.\nInvestors are feeding on this stock\nShares of AppHarvest had a solid gain of more than 8% on Monday afternoon. The stock only recently came public through a merger with aspecial purpose acquisition company, and this was the first chance that investors had to see the sustainable-farming company's full potential.\nAppHarvest released its first-quarter financial reporton Monday, and shareholders liked what they saw. The company posted $2.3 million in revenue in its first operational quarter, selling 3.8 million pounds of tomatoes from its first greenhouse facility in Kentucky. AppHarvest posted considerable losses, as expected, but it has high hopes for the future.\nIn particular, AppHarvest said that it had fully planted its 60-acre facility as of the first week of May, which should lead to capacity harvests for the foreseeable future as indoor farming makes all-year growing possible. The company has seen strong demand from customers like grocery-giantKroger and fast-food restaurant chainWendy's and anticipates more interest as it develops additional facilities.\nAppHarvest won't be profitable in the near term, but shareholders are still excited about its growth potential. With sustainable farming potentially making it possible to feed an increasingly hungry world, the stock is an interesting way to invest in agriculture.\nHere's a healthy pick\nMeanwhile, Summit Therapeutics did even better, as its stock soared 22%. The developmental-stage biopharmaceutical company's financial report didn't feature very attractive numbers, but investors are optimistic about the progress it has made recently.\nSummit's financials were predictably ugly. Revenue was just $192,000, leading to losses of $17.5 million. Summit is burning cash to conduct clinical trials, and until one of the treatments in the company's pipeline pans out, investors can expect those losses to continue. However, the company noted that CEO and majority shareholder Robert Duggan provided an additional $55 million in debt financing during the first three months of 2021, helping to boost Summit's cash levels back above the $100 million mark.\nMoreover, Summit had promising news in its business update. Phase 3 trials for its ridinilazole antibiotic are ongoing, with support from the federal government's Biomedical Advanced Research and Development Authority. Moreover, the company just launched a new study for adolescents, hoping to establish a favorable safety profile as a complement to its concurrent phase 3 program.\nSummit's share price has been volatile as investors try to determine whether the company will find success with its clinical program. As with most companies in the industry, Summit could see either massive upside or suffer big losses depending on what happens with ridinilazole and the other candidates in its pipeline.","news_type":1,"symbols_score_info":{"APPH":0.9,"SMMT":0.9}},"isVote":1,"tweetType":1,"viewCount":485,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":29,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/194026775"}